<DOC>
	<DOCNO>NCT01386294</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness intravaginal 1 % tenofovir gel prevent Human Immunodeficiency Virus ( HIV-1 ) infection Herpes Simplex Virus ( HSV-2 ) infection sexually active woman .</brief_summary>
	<brief_title>Safety Effectiveness Tenofovir Gel Prevention Human Immunodeficiency Virus ( HIV-1 ) Infection Women Effects Tenofovir Gel Incidence Herpes Simplex Virus ( HSV-2 ) Infection</brief_title>
	<detailed_description>This phase III , multicenter trial ass safety effectiveness 1 % tenofovir gel , administer vaginally approximately 2900 sexually active woman high risk sexually transmit HIV . Approximately 2600 woman age 18-30 year old enrol achieve require number endpoint show effect HIV-1 infection , 300 additional woman age 31-40 year old enrol collect safety information age group . This event driven study plan randomize seronegative woman . Participants randomize 1:1 ratio receive 1 % tenofovir gel placebo gel . Each ask insert dose assign study product within 12 hour prior coital event another dose soon possible within 12 hour coital event . Participants advise use two dos gel 24 hour period . All woman evaluate rate adverse event rate HIV seroconversion . In addition , study evaluate several secondary endpoint bear directly potential risk benefit vaginal tenofovir gel use .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Confirmed age 1840 year ( inclusive ) Able willing provide write informed consent Able willing provide adequate locator information study retention safety purpose Sexually active , define vaginal intercourse least twice past 30 day prior screen HIV negative two rapid test perform study staff within 30 day enrolment ( see algorithm Appendix 3 ) . No evidence glycosuria No evidence proteinuria great trace* No history pathological bone fracture Have negative pregnancy test Women currently breastfeed may enrol study Agree use studyapproved effective nonbarrier form contraception Agree adhere study visit procedure Willing use study gel advise Not use take follow group medication : Nephrotoxic agent Drugs slow renal excretion Immune system modulators Other antiretrovirals History adverse reaction latex . Plans follow study period To travel away study site 30 consecutive day . To relocate away study site . To become pregnant . To enrol study investigational product behaviour modification relate HIV prevention . If opinion examine clinician , sexually active Inadequate renal function ( serum creatinine great 1.5mg/dl creatinine clearance less 50ml/min , estimate use method Cockcroft Gault96 ) Grade 3 ALT AST screen clinical sign liver disease ( e.g . ascites , hepatomegaly , jaundice ) Abnormal serum phosphate level ( Grade 3 ) Has clinically apparent find speculum pelvic examination ( observed study staff ) involve deep epithelial disruption . Otherwise eligible participant speculum pelvic examination finding involve deep epithelial disruption may proceed enrolment finding resolve inclusion/exclusion met . Received previously receive experimental HIV vaccine Currently participate another HIV prevention intervention study participation clinical trial biomedical intervention last six month Has current STI symptom and/or reproductive tract infection require treatment , assess study staff . Otherwise eligible participant diagnose screen infection ( ) require treatment may enrol provide treatment complete . Any clinical evidence untreated cervical abnormality Has condition , base opinion Investigator designee , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>